Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Mutated regions of nucleophosmin 1 elicit both CD4 + and CD8 + T-cell responses in patients with acute myeloid leukemia

Jochen Greiner, Yoko Ono, Susanne Hofmann, Anita Schmitt, Elmar Mehring, Marlies Götz, Philippe Guillaume, Konstanze Döhner, Joannis Mytilineos, Hartmut Döhner, Michael Schmitt

Blood (2012) 120 (6): 1282–1289.

https://doi.org/10.1182/blood-2011-11-394395

Published: 2012

Journal Articles

Coexpression of the T-cell receptor constant α domain triggers tumor reactivity of single-chain TCR-transduced human T cells

Ralf-Holger Voss, Simone Thomas, Christina Pfirschke, Beate Hauptrock, Sebastian Klobuch, Jürgen Kuball, Margarete Grabowski, Renate Engel, Philippe Guillaume, Pedro Romero, Christoph Huber, Philipp Beckhove, Matthias Theobald

Blood (2010) 115 (25): 5154–5163.

https://doi.org/10.1182/blood-2009-11-254078

Published: 2010

Includes: Supplemental data

Journal Articles

RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses

Blood (2008) 111 (3): 1357–1365.

https://doi.org/10.1182/blood-2007-07-099366

Published: 2008

Journal Articles

Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.

Fei Fei, MD, Yingzhe Yu, Anita Schmitt, MD, Jinfei Chen, PhD, MD, Baoan Chen, PhD, MD, Markus Rojewski, MD, Mark Ringhoffer, MD, Stefanie von Harsdorf, MD, Jochen Greiner, PhD, MD, Marlies Goetz, Philippe Guillaume, PhD, Hartmut Dohner, PhD, MD, Donald Bunjes, PhD, MD, Michael Schmitt, PhD, MD

Blood (2007) 110 (11): 2368.

https://doi.org/10.1182/blood.V110.11.2368.2368

Published: 2007

Journal Articles

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Jochen Greiner, MD, Anita Schmitt, MD, Krzysztof Giannopoulos, MD, Jinfei Chen, MD, Marlies Goetz, Markus Rojewski, MD, Gerd Ritter, PhD, Sascha Gnjatic, PhD, Philippe Guillaume, PhD, Mark Ringhoffer, MD, Martin Bommer, MD, Richard F. Schlenk, MD, Peter Liebisch, MD, Donald Bunjes, MD, Hiroshi Shiku, PhD, Hartmut Dohner, MD, Michael Schmitt, MD

Blood (2007) 110 (11): 1806.

https://doi.org/10.1182/blood.V110.11.1806.1806

Published: 2007

Journal Articles

Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.

Jinfei Chen, MD, Anita Schmitt, MD, Baoan Chen, MD, Markus Rojewski, MD, Jochen Greiner, MD, Philippe Guillaume, PhD, Hartmut Dohner, MD, Donald Bunjes, MD, Michael Schmitt, PhD

Blood (2006) 108 (11): 2201.

https://doi.org/10.1182/blood.V108.11.2201.2201

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Mutated regions of nucleophosmin 1 elicit both CD4 + and CD8 + T-cell responses in patients with acute myeloid leukemia

Coexpression of the T-cell receptor constant α domain triggers tumor reactivity of single-chain TCR-transduced human T cells

RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses

Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.

Email alerts

ASH Publications

American Society of Hematology

Update search

Mutated regions of nucleophosmin 1 elicit both CD4 + and CD8 + T-cell responses in patients with acute myeloid leukemia

Coexpression of the T-cell receptor constant α domain triggers tumor reactivity of single-chain TCR-transduced human T cells

RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses

Tyrosine Kinase Inhibitors Dasatinib, Nilotinib and Imatinib Have an Impact on Both CD8+ T Lymphocytes and CD4+CD25+FoxP3+ Regulatory T Cells by Downregulation of the NF-κB Pathway.

Immunological and Clinical Responses in Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL) after RHAMM-R3 Peptide Vaccination.

Imatinib Inhibits Both CD4+ T Regulatory Cells and CD8+ T Lymphocytes Specifically Directed Against the Leukemia-Associated Antigen RHAMM/CD168.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only